Management of severe asthma: A European Respiratory Society/American Thoracic Society guideline

Fernando Holguin, Juan Carlos Cardet, Kian Fan Chung, Sarah Diver, Diogenes S. Ferreira, Anne Fitzpatrick, Mina Gaga, Liz Kellermeyer, Sandhya Khurana, Shandra Knight, Vanessa M. McDonald, Rebecca L. Morgan, Victor E. Ortega, David Rigau, Padmaja Subbarao, Thomy Tonia, Ian M. Adcock, Eugene R. Bleecker, Chris Brightling, Louis Philippe BouletMichael Cabana, Mario Castro, Pascal Chanez, Adnan Custovic, Ratko Djukanovic, Urs Frey, Betty Frankemölle, Peter Gibson, Dominique Hamerlijnck, Nizar Jarjour, Satoshi Konno, Huahao Shen, Cathy Vitary, Andy Bush

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

This document provides clinical recommendations for the management of severe asthma. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the European Respiratory Society/American Thoracic Society Task Force's questions. The evidence was appraised using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of asthma experts, who made specific recommendations on six specific questions. After considering the balance of desirable and undesirable consequences, quality of evidence, feasibility, and acceptability of various interventions, the Task Force made the following recommendations: 1) suggest using anti-interleukin (IL)-5 and anti-IL-5 receptor α for severe uncontrolled adult eosinophilic asthma phenotypes; 2) suggest using a blood eosinophil cut-point ≥150 μL−1 to guide anti-IL-5 initiation in adult patients with severe asthma; 3) suggest considering specific eosinophil (≥260 μL−1) and exhaled nitric oxide fraction (≥19.5 ppb) cut-offs to identify adolescents or adults with the greatest likelihood of response to anti-IgE therapy; 4) suggest using inhaled tiotropium for adolescents and adults with severe uncontrolled asthma despite Global Initiative for Asthma (GINA) step 4-5 or National Asthma Education and Prevention Program (NAEPP) step 5 therapies; 5) suggest a trial of chronic macrolide therapy to reduce asthma exacerbations in persistently symptomatic or uncontrolled patients on GINA step 5 or NAEPP step 5 therapies, irrespective of asthma phenotype; and 6) suggest using anti-IL-4/13 for adult patients with severe eosinophilic asthma and for those with severe corticosteroid-dependent asthma regardless of blood eosinophil levels. These recommendations should be reconsidered as new evidence becomes available.

Original languageEnglish (US)
Article number1900588
JournalEuropean Respiratory Journal
Volume55
Issue number1
DOIs
StatePublished - Jan 1 2020

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Management of severe asthma: A European Respiratory Society/American Thoracic Society guideline'. Together they form a unique fingerprint.

  • Cite this

    Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., McDonald, V. M., Morgan, R. L., Ortega, V. E., Rigau, D., Subbarao, P., Tonia, T., Adcock, I. M., Bleecker, E. R., Brightling, C., ... Bush, A. (2020). Management of severe asthma: A European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 55(1), [1900588]. https://doi.org/10.1183/13993003.00588-2019